NCT02140801View on ClinicalTrials.gov

Optical Coherence Tomography to Evaluate Ticagrelor and Clopidogrel

PHASE4CompletedINTERVENTIONAL
Enrollment

352

Participants

Timeline

Start Date

May 1, 2014

Primary Completion Date

March 8, 2017

Study Completion Date

March 8, 2017

Conditions
Thrombosis
Interventions
DRUG

Ticagrelor

Plain, round, yellow, filmcoated tablet, 90 mg

DRUG

Clopidogrel

Orange brown capsule, containing one 75 mg clopidogrel tablet (cut into 2 halves)

Trial Locations (1)

210006

Nanjing First Hospital, Nanjing

All Listed Sponsors
lead

Nanjing First Hospital, Nanjing Medical University

OTHER

NCT02140801 - Optical Coherence Tomography to Evaluate Ticagrelor and Clopidogrel | Biotech Hunter | Biotech Hunter